1061358-78-8 Usage
Description
6-Chloro-3-trifluoromethylpyridin-4-ylamine is an organic compound characterized by its chloro and trifluoromethyl functional groups attached to a pyridine ring. It is a versatile intermediate in the synthesis of various pharmaceuticals, agrochemicals, and other specialty chemicals due to its unique structural features and reactivity.
Uses
Used in Pharmaceutical Industry:
6-Chloro-3-trifluoromethylpyridin-4-ylamine is used as a key intermediate for the synthesis of various pharmaceutical compounds. Its presence in the molecular structure can enhance the biological activity and pharmacological properties of the final drug products, making it a valuable building block in drug discovery and development.
Used in Agrochemical Industry:
In the agrochemical industry, 6-Chloro-3-trifluoromethylpyridin-4-ylamine is utilized as a starting material for the development of novel pesticides and insecticides. Its unique chemical structure can provide new modes of action and improved efficacy against pests and diseases, contributing to more sustainable agricultural practices.
Used in Organic Synthesis:
6-Chloro-3-trifluoromethylpyridin-4-ylamine is a useful research chemical for organic synthesis and other chemical processes. Its reactivity and functional group compatibility make it a valuable component in the synthesis of complex organic molecules, including specialty chemicals, dyes, and advanced materials.
Used in Chemical Research:
As a research chemical, 6-Chloro-3-trifluoromethylpyridin-4-ylamine is employed in academic and industrial laboratories to study its chemical properties, reactivity, and potential applications in various fields. Its unique structure and functional groups make it an interesting subject for exploring new synthetic routes and developing innovative chemical processes.
Check Digit Verification of cas no
The CAS Registry Mumber 1061358-78-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,6,1,3,5 and 8 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1061358-78:
(9*1)+(8*0)+(7*6)+(6*1)+(5*3)+(4*5)+(3*8)+(2*7)+(1*8)=138
138 % 10 = 8
So 1061358-78-8 is a valid CAS Registry Number.
1061358-78-8Relevant articles and documents
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)
Osborne, James D.,Matthews, Thomas P.,McHardy, Tatiana,Proisy, Nicolas,Cheung, Kwai-Ming J.,Lainchbury, Michael,Brown, Nathan,Walton, Michael I.,Eve, Paul D.,Boxall, Katherine J.,Hayes, Angela,Henley, Alan T.,Valenti, Melanie R.,De Haven Brandon, Alexis K.,Box, Gary,Jamin, Yann,Robinson, Simon P.,Westwood, Isaac M.,Van Montfort, Rob L. M.,Leonard, Philip M.,Lamers, Marieke B. A. C.,Reader, John C.,Aherne, G. Wynne,Raynaud, Florence I.,Eccles, Suzanne A.,Garrett, Michelle D.,Collins, Ian
, p. 5221 - 5237 (2016/07/06)
Multiparameter optimization of a series of 5-((4-aminopyridin-2-yl)amino)pyrazine-2-carbonitriles resulted in the identification of a potent and selective oral CHK1 preclinical development candidate with in vivo efficacy as a potentiator of deoxyribonucleic acid (DNA) damaging chemotherapy and as a single agent. Cellular mechanism of action assays were used to give an integrated assessment of compound selectivity during optimization resulting in a highly CHK1 selective adenosine triphosphate (ATP) competitive inhibitor. A single substituent vector directed away from the CHK1 kinase active site was unexpectedly found to drive the selective cellular efficacy of the compounds. Both CHK1 potency and off-target human ether-a-go-go-related gene (hERG) ion channel inhibition were dependent on lipophilicity and basicity in this series. Optimization of CHK1 cellular potency and in vivo pharmacokinetic-pharmacodynamic (PK-PD) properties gave a compound with low predicted doses and exposures in humans which mitigated the residual weak in vitro hERG inhibition.
